Table 2.
Treatment Parameters
| Recurrence Treatment Group (n = 12) | Primary Treatment Group (n = 14) | |
|---|---|---|
| Concurrent chemotherapy | 3 patients vinorelbin 4 patients capecitabin 1 patient sunitinib 1 patient doxorubicin |
1 patient vinorelbin 1 patient capecitabin |
| PTV localization/extensiona | ||
| a) Ipsilateral chest wall | 2 patients | 2patients |
| b) More than 1/2 of the thoracic circumference plus loco-regional lymph nodes | 4 patients | 9 patients |
| c) More than 2/3 of the thoracic circumference plus loco-regional lymph nodes | 6 patients | 3 patients |
| d) Extranodal metastasis within the PTV | 1 patient (pleura) | 2 patients (bone lesions) |
| e) Extensive skin metastases | 4 patients | |
| PTV volume (cm3) | 2984 (1457–6837) | 1330 (520–6623) |
| Cranio-caudal PTV extension (cm) | 30 (19–52) | 28 (18,2–43,5) |
| Median total dose | 40 Gy (32–60 Gy) | 50 Gy (40–60 Gy) |
| Median dose per fraction | 2 Gy (1,8–3,0 Gy) | 2,0 Gy (1,5–2,24 Gy) |
| Simultaneous integrated boost | 2 patients (50.4/56 Gy with single doses of 1.8/2.0Gy; 55,8/60,1 Gy with single doses of 1.8/1.94 Gy) |
3 patients (45/50 Gy with single doses of 1.8/2.0 Gy; 45/50/56 Gy with single doses of 1.8/2.0/2.24 Gy; 46Gy/50 with single doses of 2.0/2.17 Gy) |
| Neutron boost | 6 patients (4.6–12Gy) | − |
aThe PTV comprised more than a hemi-thorax in 13 and more than two thirds of the thoracic circumference in 9 patients